Lakefront Biotherapeutics NV heads into the final week of September with a sharp 10% weekly gain and a lending market that offers almost no friction for either side of the trade.
The price story is straightforward. LKFT closed at €26.36 on September 22, up 2.8% on the day and 10.4% on the week — the strongest seven-day move of the recent period, extending a 5.8% one-month drift higher. What makes that move interesting is how little short-side conviction it has attracted. Short interest is marginal at roughly 0.4% of free float, and availability in the lending pool is effectively unconstrained — running near 1,900%, meaning there are nearly nineteen shares available to borrow for every one currently lent out. That is well above even the most generous "normal" threshold. The 52-week low for availability was 255%, itself an extremely loose reading. Borrow cost ticked up to 2.4% annualised on September 22 from 1.9% the prior session, but the month-on-month trend is down roughly 20%. None of this points to a lending-market squeeze or meaningful short-side pressure building behind the rally.
The ORTEX short score of 32.9 reinforces that picture. A reading in the low 30s places the stock well below any level associated with elevated short conviction, and the score has been essentially flat across the past two weeks — ranging between 32.9 and 33.5 with no directional drift. The factor short-score rank of 71 captures the same message: the vast majority of stocks in the ORTEX universe carry higher short-side pressure than LKFT does right now. Positioning looks uncontested rather than contested.
The ownership register is the more newsworthy data point this week. Gilead Sciences holds 51.4% of shares as of the June 30 filing, having roughly doubled its position — adding 16.7 million shares in the most recent period. That half-and-half structure largely determines sentiment: with a strategic biopharma anchor holding the majority, near-term moves in the remaining float are driven by a small cluster of specialist investors. Tang Capital Management (7.8%), Van Herk Investments (7.1%), and Madison Avenue Partners (5.3%, which added 3.6 million shares in the quarter) collectively control another 20% of the register. The most recent insider data is stale — the last filed trades are from May 2026, when CEO Henry Gosebruch and CFO Aaron Cox each bought in the low-to-mid €23 range. At €26.36 those purchases are now modestly in the money, but the data is too old to draw current-sentiment conclusions.
Valuation multiples reflect the biotech's pre-profitability stage. The price-to-book reads 0.69, up 18 cents over the past month — the one multiple showing a meaningful positive move as the stock has rallied. The earnings yield is negative, and the EV/EBITDA of 6.9x has compressed about 1.65 turns over 30 days. Correlated peers on the week offer a mixed backdrop: NTRA rallied 11.4% — almost exactly matching LKFT's own move — while BMRN slipped 1.7% and ABOS fell 8.3%. The absence of a uniform sector direction suggests LKFT's week was driven by its own specific flow rather than a broad biotech lift.
The next scheduled earnings event falls on November 11. With borrow availability showing no sign of tightening and short interest remaining near zero, the run-up to that date is less a story about short-side dynamics and more about whether Gilead's strategic ownership and the specialist-fund holder base generate any fresh activity ahead of what will be the next meaningful information release.
See the live data behind this article on ORTEX.
Open LKFT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
